



## RESEARCH ARTICLE



Received on: 25-7-2014 Accepted on: 30-08-2014 Published on: 15-09-2014

#### Payghan S.A

Tatyasaheb Kore College of Pharmacy, Warananagar, Panhala, Dist: Kolhapur 416 113 MS. India Email: <u>sapayghan.tkcp@gmail.com</u> Phone No: +919096202858



**QR Code for Mobile users** 

Conflict of Interest: None Declared !

DOI: 10.15272/ajbps.v4i35.574

## Stability Study of Griseofulvin in Non Aqueous Microemulsion System

Jadhav C.M.; Kate V. K., Payghan S.A\*

Tatyasaheb Kore College of Pharmacy, Warananagar, Panhala, Dist: Kolhapur 416 113 MS. India

#### Abstract

New non aqueous based microemulsion allows the delivery of storage sensitive personal care actives in conventional cream, lotion and gel. Griseofulvin is an antifungal antibiotic drug micro emulsion system as the basic formulation for investigation. The quantity of griseofulvin and the accumulation of anhydrous micro emulsions at various temperatures were analyzed with poor aqueous solubility. It is thought to inhibit fungal cell mitosis and nuclear acid synthesis. Pharmaceutical and cosmetic micro emulsions are normally oil-in-water (o/w) or water-in-oil (w/o) systems; however, micro emulsions can be formulated with no aqueous phase to produce an anhydrous micro emulsion system. An anhydrous micro emulsion system could offer a stable vehicle for compounds that are sensitive to hydrolysis or oxidation. Therefore, to enhance the stability of griseofulvin in formulations, we chose the non aqueous, anhydrous through an established ultra violet (uv) method. The results indicated that Stability of griseofulvin in non aqueous microemulsion carried out at at temperature 5°C, 25°C and 40°C. Cream was stable at 5°C and 25°C. Stability studies were carried out at agitation, centrifugation, freeze thaw cycle, in that evaluated various parameter i.e phase separation, globule size, viscosity, drug content.

Keywords: Non-aqueous micro emulsion; Griseofulvin; stability

Cite this article as:

Jadhav C.M.; Kate V. K., Payghan S.A. Stability Study of Griseofulvin in Non Aqueous Microemulsion System. Asian Journal of Biomedical and Pharmaceutical Sciences; 04 (35); 2014; 79-83.

### **INTRODUCTION**

Griseofulvin is an antifungal substance typically produced by the growth of certain strains of Penicillium griseofulvum<sup>1</sup>. Griseofulvin is usually given systemically, beneficial responses in fungal skin infections have been reported with some topical formulations. Griseofulvin is also used as a veterinary antifungal drug. Griseofulvin's spectrum of activity is limited to dermatophytes and these fungi possess a prolonged energy-dependent transport system for the antibiotic. In contrast, in insensitive organisms, such as *C. albicans*, this system is replaced by a short-energy-independent transport system<sup>2</sup>. In the case of topical drug delivery, the diffusion takes place mainly through the stratum corneum (lipoidial barrier). The drug allows different path to permeate through stratum corneum. Owing to poor aqueous solubility griseofulvin cannot permeate through the skin to its less solubility in water than required for crossing the skin barrier<sup>1,2</sup>.

Definition of emulsion doesn't explain that which type of two immiscible liquids will be use in formulation. Conventionally water is one of the liquid phase in formulation of emulsion, but emulsion can be formulated without an aqueous phase to produce anhydrous, non aqueous or oil in oil emulsion. Such systems can replace conventional emulsion, that means there is no restriction regarding selection of two immiscible phases therefore it may be of oil-oil, oilwater/water oil or polar solvent-oil. Non-aqueous emulsions, however, could replace regular aqueous emulsions wherever the presence of water is undesirable; for example, incorporating drugs susceptible to hydrolysis. There have been only occasional reports on non-aqueous emulsion systems<sup>3,4</sup>. Non-aqueous emulsions may be of pharmaceutical or cosmetic value if they are composed primarily of edible, non-toxic ingredients and can be formulated to exhibit a wide range of physical properties<sup>5,6</sup>. Some possible uses might be as topical application bases for dermatological, particularly for labile drugs, as emollient bases for cosmetic preparations, or as nutrient preparations. Thus, they can be used alone or combined with cosmetic ingredients to form a number of over-the-counter (OTC) personal care products. The stabilization of emulsions composed of non-toxic, pharmaceutically relevant substances where olive oil or mineral oil were used as non-polar phase, glycerin as polar phase and conventional emulsifiers as stabilizing agents<sup>6</sup>. After comprehensive screening of existing low molecular emulsifiers, it was found that non-aqueous emulsions could be stabilized with amphiphilic surfactants which have attraction for the polar and the non-polar phase. Increasing the viscosity of the continuous phase improved emulsion stability<sup>7,8,9</sup>.

## EXPERIMENTAL

#### Materials

Griseofulvin (Mahaluxmi chemie, Hyderabad), Glycerin (Loba Chemical, Mumbai), Olive oil (Poona chemical laboratory, Pune), Glycerol mono stearate, (Research lab fine chemical industry, Mumbai) were received as gift sample. Methanol, Chloroform, distilled water, phosphate buffer pH (7.4) were also used throughout the study. All other chemicals and reagent were of analytical grade and were used without further purification.

## Formulation of NAME, AME

Non aqueous microemulsion and aqueous microemulsion was prepared with the help of titration method (Table 1)<sup>9, 10,26</sup>. After preparing Microemulsion evaluated by agitation, centrifugation and freeze thaw cycle method using UV method.

Formulation Type	Drug (mg)	Oil (%)	S/Cos mix (%)	Glycerin (%)	Water (%)
NAME	500	59.32	29.85	15.25	-
Aqueous Formulation	500	59.32	29.85	-	15.25

**Table 1:** Compositions of NAME and AME used

## Stability Test

#### **Agitation test**

5 gm of the non-aqueous cream was filled in a container and container was placed on a reciprocating shaker. The container was shaken at room temperature approximately 60 cycles per minute at for 24 hrs. After 24 hrs container was removed and cream was observed for any signs of phase separation<sup>11</sup>.

## **Centrifugation test**

Centrifugation test was performed immediately after formulation of the non-aqueous cream. 5 gm of nonaqueous cream was filled in a centrifuge tube. The tubes containing non-aqueous cream were subjected to centrifugation at 3500 rpm for 30 minutes. Cream was observed for any signs of phase separation after the test<sup>12</sup>.

#### Freeze-thaw cycles

During this test non-aqueous cream was subjected to cyclic temperature testing. Three freeze-thaw cycles were carried out between freezer temperature (-10°C) and 25°C. Firstly, samples were stored in freezer for 48 hrs. After 48 hrs, samples were taken out from freezer and kept at 25°C for 48 hrs. Procedure was repeated for three times. After each storage period stability of cream was checked in terms of phase separation, cracking etc. Also viscosity of the formulation was measured before and after the freeze-thaw cycling<sup>13</sup>.

### Accelerated stability study

Investigation of physical changes in an optimized nonaqueous cream was performed by accelerated stability study. Samples of optimized formulation were kept in refrigerator and programmable environmental chamber for three months at 5°C  $\pm$  2°C, 25°C and 60% RH and elevated temperature 40°C  $\pm$  2°C and 75 % RH  $\pm$  5 % RH. Samples were withdrawn at 1, 2 and 3 months from the time of placing sample into the chamber. At these time intervals formulation was monitored for changes in color, viscosity and drug content<sup>14</sup>.

# Sample Preparation and Ultra violet spectroscopy (UV) Analysis

For sample preparation, 0.25 g of emulsion was dissolved in 50 mL of methanol and then sonicated for 30 min in a water bath sonicator. The extracted sample was subsequently diluted for analysis in pure methanol. After dilution analyse the sample at UV Wavelength was set to 291 nm<sup>15</sup>. The amount of drug content in aqueous and non aqueous microemulsion was calculated (Figure 3.2).

## **RESULTS AND DISCUSSION**

## Agitation

Droplets of the emulsion exhibit brownian movement. It is believed that no coalescence of droplets takes place unless droplets impinge upon each other owing to their Brownian movement. Agitation can contribute to the energy with which two droplets impinge upon each other. After agitation on a reciprocating shaker for 24 hrs, there was no phase separation in non-aqueous cream which indicates it has good stability<sup>16</sup> and can withstand the mechanical forces during the transportation and handling.

Study parameter	Evaluation parameter of Trial Batches						
		Ι	II	II	Remark		
Agitation (37±°C)	Phase separation	No	No	No	No phase separation occurs		
	Viscosity (cPs)	11250 ±0.133	11239 ±0.1347	11231 ±0.1278	Viscosity slightly changes		
Centrifugation (37±°C)	Phase separation	No	No	No	No phase separation occurs		
	Viscosity (cPs)	11250 ±0.127	11210 ±0.1345	11164 ±013.74	Viscosity slightly changes		

**Table 3.2:** Stability study of NAME by Agitation and Centrifugation

 **Centrifugation**

Shelf life of emulsion under normal storage conditions can be predicted by observing the separation of the dispersed phase due to either creaming or coalescence when emulsion was an exposed to centrifugation. Stokes' law shows that creaming is function of gravity and increase in gravity accelerates separation<sup>17</sup>. Centrifugation test was carried out to examine the effect of gravity on the non-aqueous cream. Non-aqueous cream showed no phase separation after centrifugation for 30 minutes at 3500 rpm. This indicates that cream has a good stability over the gravitational forces.

## Accelerated stability study

The chemical and physical stability of the non-aqueous cream was evaluated through accelerated stability studies. During studies, formulation was kept at three temperature conditions: low temperature (5°C), moderate temperature (25°C) and high temperature (40°C) <sup>19, 20,21,22,23</sup>. Formulation was monitored for changes in color, viscosity and drug content for the period of three months.

## Stability study at 5°C

There was slight decrease in the drug content at  $25^{\circ}$ C. Drug content was decreased from  $98.13\pm0.56$  to  $97.50\pm0.35\%$  within three months. As seen in case of low temperature, there was initial increase in viscosity followed by decrease upto 9369 cPs. Greater decrease in viscosity was observed due to increase in temperature. Also there was slight change in the color of the formulation; color was changed from fresh white to dull white.

## Stability study at 25°C

Drug content of the non-aqueous cream was found to be constant at 5°C. There was no significant change in the chemical composition of the formulation<sup>24</sup>. But there were some changes in the viscosity of the formulation. Initial viscosity of the formulation was found to be 11043 cPs up to 1 month, thereafter there was increase in the viscosity up to 129800 cPs, and globule size is slightly changes. Color of the formulation didn't change at the low temperature. So it was observed that nonaqueous cream was stable at low temperature.

### Stability study at 40°C

It was observed that non-aqueous cream was very sensitive to the high temperature. A distinct phase separation occurred within a week<sup>25</sup>. So stability study at high temperature was terminated. From stability studies it was evident that non-aqueous cream was stable at low and moderate temperatures. All this study comparing with the aqueous formulation was indicative.






Figure 3.1: Viscosity changes after stability study

Tempecture	Duration (Months)	Appearance	Viscosity (cPs)	Globule size (nm)	Drug content (%)	Stability / Phase separation
NAME ( 25°C)	0	White	11043	69	98.75	No phase separation
	0	White	± 0.93	±0.34	±0.13	
	1	White	12980	67	98.13	
	1		± 0.86	±0.91	±0.13	
	2	White	10963	64	98.13	
			± 0.76	±0.78	±0.13	
	3	White	9396	61	97.50	
	5		± 0.34	±0.46	±0.13	
	0	White	11043	74	98.13	No phase separation
	0		± 0.67	±0.23	±0.13	
	1	White	12560	71	98.52	
NAME	1		± 0.87	±0.98	±0.12	
	2	White	11345	64	98.44	
	2		± 0.54	±0.43	±0.11	
	3	Dull White	10351	62	98.03	
			± 0.12	±0.89	±0.11	
	0	White	11043	56	98.35	Phase separation within 2 month
			± 0.99	±0.74	±0.13	
-	1	White	10934	43	96.23	
NAME			± 0.98	±0.71	±0.12	
(40°C)	2	Dull white	9835	41	94.89	
			± 0.84	±0.65	±0.11	
	3	Dull white	6035	39	93.56	
			± 0.67	±0.67	±0.10	
— Aqueous cream — —	0	White	8953	56	99.89	No phase separation
			± 0.34	±0.54	±0.13	
	1	White	8123	51	98.45	
			± 0.97	±0.34	±0.12	
	2	Dull white	7903	47	98.10	
			± 0.56	±0.32	±0.13	
	3	Brown	6452	45	97.45	
			$\pm 0.45$	±0.14	±0.13	

**Table 3.3:** Stability studies of non-aqueous cream at 25°C and 5°C





#### CONCLUSION

The stability of griseofulvin in non aqueous microemulsion system was examined therefore, in the first part of the study; we used two Glycerine-in-olive oil anhydrous emulsions formulations containing griseofulvin. Secondly, all parameter were compared with aqueous micro emulsion of Griseofulvin. The stability study of all NAME and AME formulations were determined at various temperatures conditions. The non aqueous microemulsion were mostly stable at 25°C and 5°C Thus, the difference in the stability of griseofulvin in these non aqueous micro emulsions will be revealed by this study.

#### ACKNOWLEDGEMENT

We express our sincere gratitude to Principal, Tatyasaheb Kore College of Pharmacy Warananagar for providing laboratory facilities.

#### REFERENCES

1. Aggarwal, N., Kurane , R., Formulation ,characterization and evaluation of an optimized microemulsion formulation of griseofulvin for topical application, Journal colloids and surfaces B:Biointerface 105 (2013)158-166

#### http://dx.doi.org/10.1016/j.colsurfb.2013.01.004

2. Sable, V, Formulation and evaluation of microemulsion based hydrogel for topical delivery,. International journal of pharmaceutical investigation july 2012, vol 2, Issue 3

3. Payghan SA, Bhat M, Shrivastava DN, Toppo E, Purohit S. Nonaqueous emulsion: Versatile vehicle for drug delivery. Pharmainfo.net. 2008; Vol. 6 Issue 1.

4. Baravkar V. S., Jirage A. S., Kate V. K., Payghan S. A.; Potential Application of Non Aqueous Emulsion for Drug Delivery, Asian Journal of Biomedical and Pharmaceutical Sciences; Volume

#### Payghan et al: Asian Journal of Biomedical and Pharmaceutical Sciences; 4(35) 2014, 71-75.

04,(29); 2014; 10-18. [ISSN 2249-622X] http://dx.doi.org/10.15272/ajbps.v4i29.461

5. Sakthivel, T., Jaitely, V., Patel, N.V., Florence, A.T., 2001. Nonaqueous emulsions: hydrocarbon-formamide systems. International Journal of Pharmaceutics 214, 43–48. http://dx.doi.org/10.1016/S0378-5173(00)00629-3

6. Jadhav, C. M., Shinde S. M., Kate V. K., Payghan S. A. Investigating application of non aqueous microemulsion for drug delivery. Asian Journal of Biomedical And Pharmaceutical Sciences, 4(29) 2014, 1-9. <u>http://dx.doi.org/10.15272/aibps.v4i29.460</u>

7. Hamill, R.D., Petersen, R.V., 1966b. Effects of ageing and surfactant concentration on the rheology and droplet size distribution of a non aqueous emulsion. Journal of Pharmaceutical Sciences 55, 1269–1277.

#### http://dx.doi.org/10.1002/jps.2600551120

8. Reichmann, K.W., Petersen, R.V., 1973. Temperature studies with non-aqueous emulsions. Journal of pharmaceutical sciences 62, 1850–1856. <u>http://dx.doi.org/10.1002/jps.2600621126</u>

9. Rusmawati, W.M., Dzulkefly, K., Lim, W.H., Hamdan, S., 2002. Emulsion Properties of Mixed Tween20-Span20 in Non-Aqueous System. Pertanika journal of science and technology 10(2), 153–160.

10. Orawan, S., Jaitely, V., Florence, A.T., 2008. Exploring the Possibilities of Stable Anhydrous Emulsions. Advanced Drug Delivery Reviews 4, 5–10.

11. Magdassi, S., Frank, S.G., 1988. Formulation of oil in polyethylene glycol/water emulsions. Journal of Dispersion Science and technology 9 (4), 391–399.

http://dx.doi.org/10.1080/01932698808943997

12. Payghan, S. A., Kate, V. K., Purohit, S., Bhandari, A., Effect of Aging Condition on the Dissolution and Diffusion Stability of Non-aqueous Emulsion. Inventi Rapid; Pharma Tech, vol. 2013, Issue 3, ppt 505, 1-7, (2012). Inventi:ppt/505/12

13. Chih, C. L., Chao-Hsun, Y, Nai-Fang, C., Study on the Stability of DeoxyArbutin in an Anhydrous Emulsion System. International journal of molecular sciences 2011; 12(9): 5946–5954.

14. Imhof, A., Pine, D.J., 1997. Stability of Non aqueous Emulsions. Journal of Colloid and Interface Science 192, 368–374.

#### http://dx.doi.org/10.1006/jcis.1997.5020

15. Payghan, S. A., Kate, V. K., Purohit, S., Bhandari, A., Goodness of Fit model dependent approaches for release kinetics and In-vitro release of piroxicam from PEGS based non-aqueous emulsion. Inventi Rapid; Pharma Tech, vol. 2012, Issue 3, ppt 504, 1-8, (2012). Inventi:ppt/504/12

16. Kate VK, Payghan SA; Effect of bioadhesion and permeability on dissolution behavior of piroxicam mucoadhesive fast disintegrating tablet. Inventi Rapid: Pharm Tech April-June 2013, 2013:2: (http://www.inventi.in/Article/ppt/751/13.aspx)

17. Cameron, N.R., Sherrington, D.C., 1996. Non-aqueous high internal phase emulsions: Preparation and stability. Journal of chemical society Faraday trens 92(9), 1543–1547.

18. Kate VK, Payghan SA, Shinde AJ. Effect of aging conditions on the dissolution stability of piroxicam mucoadhesive fast disintegrating tablet, Inventi Rapid: NDDS, April - June 2013,2013:2 (http://www.inventi.in/Article/pndds/659/13.aspx)

19. Kate VK, Payghan SA, Shinde AJ. Single dose pharmacokinetics of mucoadhesive fast disintegrating sublingual tablet of piroxicam in rabbits. Inventi Impact: Pharmacokinetics & Pharmacodynamics July-Sep-2013: 3 (http://www.inventi.in/Article/pkd/97/13.aspx)

20. Khayyam, S, Patwekar, S., S. A. Payghan, J. I. Disouza; Dissolution and Stability Enhancement of Poorly Water Soluble Drug – Lovastatin by Preparing Solid Dispersions; Asian Journal of Biomedical and Pharmaceutical Sciences; Vol.1(4): 24-31,Dec-2011. 21. Shinde SM, Payghan SA. Physiochemical assessment of pharmaceutical salt Forms: a quality attribute. International Research Journal for Inventions in Pharmaceutical Sciences, 2014; 2(2): 46-53. 22. Payghan SA, Shrivastava DN, Toppo E. Potential of solubility in drug discovery and development. Oct- 2008 http://www.pharmainfo.net/reviews/potential-solubility-drug discovery -and-development

23. AS Jirage, VS Baravkar, VK Kate, SA Payghan. Poly-βhydroxybutyrate: intriguing biopolymer in biomedical applications and pharma formulation trends. International Journal of Pharmaceutical & Biological Archives 2013; 4(6): 1107 – 1118.

24. Powell, V.V., Kasson, A.E., Kilgour, J.A., 2000. Non-aqueous silicone emulsions. United States Patent number 6060546.

25. Orawan, S., Jaitely, V., Florence, A.T., 2008. Exploring the Possibilities of Stable Anhydrous Emulsions. Advanced Drug Delivery Reviews 4, 5–10.

26.Bauer, K.H., Dortunc, B., 1984. Non-aqueous emulsions as vehicles for capsule fillings. Drug Development and Industrial Pharmacy. <u>http://dx.doi.org/10.3109/03639048409040778</u>